Singulair (montelukast) Disease Interactions
There are 4 disease interactions with Singulair (montelukast):
Montelukast (applies to Singulair) neuropsychiatric disorders
Major Potential Hazard, Moderate plausibility. Applicable conditions: Psychosis, Neurotic Depression, Depression
The use of montelukast is associated with neuropsychiatric events. Patients and prescribers should be alert for neuropsychiatric events. Care should be taken before using this agent in patients with any history of mental illness. If neuropsychiatric events occur during treatment, it is recommended to carefully evaluate the risks and benefits of continuing treatment with montelukast.
Montelukast (applies to Singulair) liver disorder
Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Liver Disease
Reports of cholestatic hepatitis, hepatocellular liver-injury, and mixed-pattern liver injury have been reported in patients treated with montelukast sodium that had underlying potential for liver disease, such as alcohol use or other forms of hepatitis. Patients with mild-to-moderate hepatic insufficiency and clinical evidence of cirrhosis had evidence of decreased metabolism of montelukast. No dosage adjustment is required in patients with mild-to-moderate hepatic insufficiency. The pharmacokinetics of montelukast sodium in patients with more severe hepatic impairment or with hepatitis have not been evaluated. Use caution when prescribing montelukast to these patients.
Montelukast (applies to Singulair) PKU
Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Phenylketonuria
Singulair (brand of montelukast) chewable tablets contain 0.842 mg of phenylalanine per each 5 mg tablet. The phenylalanine content should be considered when this product is used in patients who must restrict their intake of phenylalanine (i.e. phenylketonurics).
- "Product Information. Singulair (montelukast)." Merck & Co, Inc, West Point, PA.
Montelukast (applies to Singulair) pulmonary disorders
Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Pulmonary Impairment
Patients with asthma on therapy with montelukast may present with systemic eosinophilia, sometimes presenting with clinical features of vasculitis consistent with Churg-Strauss syndrome, a condition which is often treated with systemic corticosteroid therapy. Prescribers should be alert to eosinophilia, vasculitic rash, worsening pulmonary symptoms, cardiac complications, and/or neuropathy presenting in their patients. Care should be taken before using this agent in patients with history of pulmonary disorders.
Singulair (montelukast) drug interactions
There are 86 drug interactions with Singulair (montelukast)
More about Singulair (montelukast)
- Side Effects
- During Pregnancy or Breastfeeding
- Dosage Information
- Patient Tips
- Drug Images
- Drug Interactions
- Compare Alternatives
- Support Group
- Pricing & Coupons
- En Español
- 184 Reviews
- Generic Availability
- Drug class: leukotriene modifiers
Related treatment guides
Drug Interaction Classification
|Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.|
|Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.|
|Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.|
|No interaction information available.|
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.